Bruce K. Crowther Sells 2,400 Shares of NeoGenomics, Inc. (NASDAQ:NEO) Stock
NeoGenomics, Inc. (NASDAQ:NEO) Director Bruce K. Crowther sold 2,400 shares of the company’s stock in a transaction that occurred on Tuesday, September 22nd. The stock was sold at an average price of $35.68, for a total value of $85,632.00. Following the completion of the sale, the director now owns 46,483 shares of the company’s stock, valued at $1,658,513.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
NASDAQ NEO opened at $35.82 on Friday. NeoGenomics, Inc. has a 1-year low of $18.52 and a 1-year high of $41.03. The company has a current ratio of 6.79, a quick ratio of 6.44 and a debt-to-equity ratio of 0.25. The company has a market capitalization of $3.96 billion, a PE ratio of -716.40 and a beta of 0.80. The firm’s fifty day simple moving average is $37.69 and its 200-day simple moving average is $31.52.
NeoGenomics (NASDAQ:NEO) last posted its quarterly earnings results on Tuesday, July 28th. The medical research company reported ($0.04) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.10) by $0.06. NeoGenomics had a negative net margin of 1.33% and a positive return on equity of 0.73%. The business had revenue of $86.90 million for the quarter, compared to the consensus estimate of $86.55 million. During the same period in the prior year, the business posted $0.07 earnings per share. NeoGenomics’s revenue for the quarter was down 14.6% compared to the same quarter last year. As a group, analysts predict that NeoGenomics, Inc. will post -0.01 EPS for the current year.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Cullen Frost Bankers Inc. acquired a new position in shares of NeoGenomics in the second quarter worth $31,000. Carroll Financial Associates Inc. acquired a new position in NeoGenomics during the second quarter worth $31,000. C M Bidwell & Associates Ltd. acquired a new stake in shares of NeoGenomics in the first quarter worth about $30,000. Prime Capital Investment Advisors LLC boosted its stake in shares of NeoGenomics by 108.3% during the 2nd quarter. Prime Capital Investment Advisors LLC now owns 2,083 shares of the medical research company’s stock worth $65,000 after acquiring an additional 1,083 shares in the last quarter. Finally, Jacobi Capital Management LLC boosted its stake in shares of NeoGenomics by 70.1% during the 2nd quarter. Jacobi Capital Management LLC now owns 3,401 shares of the medical research company’s stock worth $62,000 after acquiring an additional 1,401 shares in the last quarter. 91.67% of the stock is currently owned by institutional investors and hedge funds.
A number of equities research analysts have weighed in on NEO shares. Zacks Investment Research downgraded NeoGenomics from a “strong-buy” rating to a “hold” rating in a research report on Friday, August 7th. Needham & Company LLC upped their target price on NeoGenomics from $33.00 to $39.00 and gave the stock a “buy” rating in a research report on Wednesday, July 29th. BidaskClub downgraded NeoGenomics from a “strong-buy” rating to a “buy” rating in a research report on Saturday, September 5th. Morgan Stanley assumed coverage on NeoGenomics in a research report on Wednesday, September 9th. They set an “overweight” rating and a $46.00 price objective for the company. Finally, Raymond James increased their price objective on NeoGenomics from $32.00 to $40.00 and gave the company an “outperform” rating in a research report on Wednesday, July 29th. Three investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $37.50.
About NeoGenomics
NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States; and laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company’s laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories.
Featured Story: How to Profit and Limit Losses With Stop Orders
Receive News & Ratings for NeoGenomics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for NeoGenomics and related companies with MarketBeat.com’s FREE daily email newsletter.
Original Source